Aligos Therapeutics, Inc. (ALGS)
ALGS Stock Price Chart
Explore Aligos Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ALGS price movements and trends.
ALGS Company Profile
Discover essential business fundamentals and corporate details for Aligos Therapeutics, Inc. (ALGS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
70.00
Website
https://www.aligos.comCEO
Lawrence M. Blatt MBA,
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
ALGS Financial Timeline
Browse a chronological timeline of Aligos Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$2.09, while revenue estimate is $500.00K.
Earnings released on 6 Aug 2025
EPS came in at -$1.53 surpassing the estimated -$2.35 by +34.89%, while revenue for the quarter reached $965.00K , beating expectations by +122.69%.
Earnings released on 6 May 2025
EPS came in at -$2.11 surpassing the estimated -$2.80 by +24.64%, while revenue for the quarter reached $311.00K , missing expectations by -37.80%.
Earnings released on 10 Mar 2025
EPS came in at -$3.41 falling short of the estimated -$2.63 by -29.66%, while revenue for the quarter reached $629.00K , beating expectations by +25.80%.
Earnings released on 6 Nov 2024
EPS came in at -$3.07 falling short of the estimated -$2.15 by -42.79%, while revenue for the quarter reached $1.27M , beating expectations by +192.85%.
Stock split effective on 19 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Aug 2024
EPS came in at $0.75 surpassing the estimated -$4.00 by +118.75%, while revenue for the quarter reached $1.06M .
Earnings released on 7 May 2024
EPS came in at -$5.50 falling short of the estimated -$4.75 by -15.79%, while revenue for the quarter reached $986.00K .
Earnings released on 12 Mar 2024
EPS came in at -$5.50 surpassing the estimated -$6.75 by +18.52%, while revenue for the quarter reached $2.68M , beating expectations by +67.56%.
Earnings released on 2 Nov 2023
EPS came in at -$10.25 surpassing the estimated -$12.00 by +14.58%, while revenue for the quarter reached $3.24M , beating expectations by +102.44%.
Earnings released on 3 Aug 2023
EPS came in at -$10.75 surpassing the estimated -$12.50 by +14.00%, while revenue for the quarter reached $6.89M .
Earnings released on 4 May 2023
EPS came in at -$13.25 falling short of the estimated -$12.25 by -8.16%, while revenue for the quarter reached $2.72M , beating expectations by +91.76%.
Earnings released on 9 Mar 2023
EPS came in at -$12.75 falling short of the estimated -$12.25 by -4.08%, while revenue for the quarter reached $3.54M , beating expectations by +105.64%.
Earnings released on 2 Nov 2022
EPS came in at -$11.00 surpassing the estimated -$14.25 by +22.81%, while revenue for the quarter reached $4.11M , beating expectations by +447.47%.
Earnings released on 4 Aug 2022
EPS came in at -$11.75 surpassing the estimated -$16.25 by +27.69%, while revenue for the quarter reached $3.69M .
Earnings released on 4 May 2022
EPS came in at -$21.00 falling short of the estimated -$16.50 by -27.27%, while revenue for the quarter reached $2.57M , beating expectations by +17.74%.
Earnings released on 10 Mar 2022
EPS came in at -$22.25 falling short of the estimated -$20.75 by -7.23%, while revenue for the quarter reached $367.00K .
Earnings released on 4 Nov 2021
EPS came in at -$19.50 surpassing the estimated -$20.75 by +6.02%, while revenue for the quarter reached $1.54M , missing expectations by -5.68%.
Earnings released on 5 Aug 2021
EPS came in at -$19.75 surpassing the estimated -$20.25 by +2.47%, while revenue for the quarter reached $1.55M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$18.50 surpassing the estimated -$22.50 by +17.78%, while revenue for the quarter reached $910.00K , missing expectations by -15.09%.
Earnings released on 23 Mar 2021
EPS came in at -$1.09 falling short of the estimated -$0.82 by -32.93%.
Earnings released on 25 Nov 2020
EPS came in at -$11.00 falling short of the estimated -$0.78 by -1.31K%, while revenue for the quarter reached $2.03M .
Earnings released on 19 Oct 2020
EPS came in at -$0.95 .
ALGS Stock Performance
Access detailed ALGS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.